Myeloproliferative Neoplasms (MPN)

Dr. Duffield is a board-certified hematopathologist, specializing in the diagnosis of cancers that arise in the bone marrow and lymphoid tissues. She completed a pathology residency and hematopathology fellowship at the Johns Hopkins Hospital and joined the faculty of Johns Hopkins in 2010. In 2020, she joined Memorial-Sloan Kettering to become a member of the Hematopathology Service.

Constandina Herbert, MN, RN, BMTCN is the Nursing Supervisor, Blood and Marrow Transplant Clinic at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Ms. Herbert works with patients, families, and caregivers as they navigate the transplant process.

I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use

Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant.

Dr. Zeidner's research interests include discovering innovative methods to improve outcomes, drug discovery and development, and designing clinical trials in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group where we have a multitude of cutting-edge clinical trials for acute leukemia, MDS, and MPNs. Dr. Zeidner's the Principal Investigator of industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS

Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics. Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care. Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.

Dr. Shaffer is a board certified hematologist specializing in bone marrow transplantation for leukemia, myelodysplastic syndromes, lymphoma, and other bone marrow disorders. He works in a collaborative fashion with other members of our team to provide comprehensive cancer care at Memorial Sloan Kettering Cancer Center. His research focuses on the role of Natural Killer (NK) cells in outcomes after transplantation. NK cells are white blood cells that have anti-tumor and anti-infection properties. His goal is to improve the transplantation process for patients via understanding and optimizing NK

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.